Pain relief and resolution of oral and pernanal ulceration after treatment with thalidomide in a 14 year old girl with vertically acquired HIV infection is reported. (Arch Dis Child 1996; 74: 64-65) 
Recurrent mucosal ulcers of unknown aetiology are frequent in adults with advanced HIV infection, may contribute substantially to morbidity, and are often refractory to various treatments.1 We report a child infected with HIV whose chronic mucosal ulcers resolved on treatment with thalidomide. Cultures from the oral lesions were negative for bacteria, mycobacteria, fungi, and viruses as was electron microscopy for herpes particles. Treatment with anaesthetic and disinfectant mouth washes, topical corticosteroids, and oral fluconazole (100 mg/day) gave only slight relief. A painful haemorrhoidal node with several ulcerations developed. Antihaemorrhoidal suppositories and ointments were without success. At haemorrhoidectomy the deepest oral lesion was biopsied. Conventional histology including haematoxylin-eosin, Ziehl-Neelsen, Gram, Giemsa, and Grocott stains revealed chronic inflammation, but failed to detect any infectious agent. In situ hybridisation and immune histochemical analysis for herpes viruses were negative.
Prednisone 2 mg/kg/day for four days produced some pain relief and healing of the mouth ulcers. However, it was discontinued because of suspected acute infection. She then deteriorated.
Oral thalidomide (100 mg/day (3 mg/kg/day); kindly provided by Grunenthal, Germany) resulted in dramatic pain relief within three days, complete resolution of ulcers within three weeks (figure B), and in substantial improvement of the chronic gingivitis. Rectal pain disappeared and the haemorrhoidal node almost vanished. Apart from moderate fatigue, no adverse effects were observed. Discussion Dramatic responses of oropharyngeal, oesophageal, and rectal ulcerations to thalidomide, 200 mg for 14 days, have been recently reported in 19 of 20 HIV infected adults.' The mechanism of action is not known. In vitro studies have suggested that thalidomide inhibits the production of tumour necrosis factor-ot by activated monocytes,2 induces T helper cell type 2, and inhibits T helper cell type 1 cytokine production.3 The present report demonstrates that HIV infected children with mucosal ulcers of unknown aetiology may benefit from thalidomide treatment.
Recently, thalidomide has been employed successfully in the treatment of graft-versushost disease after bone marrow transplantation, systemic lupus erythematosus, and Beho;et's disease, and for the prevention of cardiac allograft rejection, suggesting that the drug is immunosuppressive.'
In the 1950s thalidomide was used as a sedative and antiemetic in pregnant women. Teratogenicity resulted in its withdrawal from use.4 Thalidomide for our patient was supplied by the manufacturer only under stringent Thalidomide treatment of mucosal ulcerations in HIV infection conditions requiring individual patient use protocol, after informed consent by the patient and parents.
Because chronic mucosal ulceration in HIV infected patients may be extremely painful, debilitating and refractory to treatment,5 thalidomide should be considered provided the teratogenic effects are disclosed and it is certain the patient is not at risk for pregnancy.
